Master Framework and Pragmatic Clinical Trial for Relapse or Refractory Acute Myeloid Leukemia

Informacje na temat projektu

IMPACT- AML

Identyfikator umowy o grant: 101104421

DOI

10.3030/101104421

Data podpisania przez KE 27 Kwietnia 2023

Data rozpoczęcia 1 Kwietnia 2023

Data zakończenia 31 Marca 2028

Finansowanie w ramach

• Health

Koszt całkowity

€ 5 988 402,50

Wkład UE

€ 5 988 402,50

Koordynowany przez

ISTITUTO ROMAGNOLO PER LO STUDIO DEI TUMORI DINO AMADORI - IRST SRL
Italy

CORDIS oferuje możliwość skorzystania z odnośników do publicznie dostępnych publikacji i rezultatów projektów realizowanych w ramach programów ramowych HORYZONT.

Odnośniki do rezultatów i publikacji związanych z poszczególnymi projektami 7PR, a także odnośniki do niektórych konkretnych kategorii wyników, takich jak zbiory danych i oprogramowanie, są dynamicznie pobierane z systemu OpenAIRE .

Rezultaty

Documents, reports (6)

"First annual ""Diagnosis and treatment"" cluster meeting report"

• Conclusions of common annual meeting of the ‘Diagnosis and treatment’ cluster• Policy brief formulating recommendations based on the research and innovation strand of the ‘Diagnosis and treatment’ annual cluster meeting

SOP for biobanking

There will be defined standard procedures and timing for uniform biobanking of AML samples

SOP for MRD in R/R AML

There will be defined standard procedures and timing for MRD of R/R AML

"Second annual ""Diagnosis and treatment"" cluster meeting report"

• Conclusions of common annual meeting of the ‘Diagnosis and treatment’ cluster• Policy brief formulating recommendations based on the research and innovation strand of the ‘Diagnosis and treatment’ annual cluster meeting

Study intiation package

Registration number of the clinical study in a registry meeting WHO Registry criteria (see also references given in subheading 1.1 of this template). Final version of study protocol as approved by the regulator(s) / ethics committee(s). Regulatory and ethics (if applicable, institutional) approvals required for the enrolment of the first study participant (In case of multicentre clinical studies, submission of approvals for the first clinical site is sufficient.)

Initial common work plan for scientific collaboration under the ‘Diagnosis and treatment’ cluster

Initial common work plan for scientific collaboration under the ‘Diagnosis and treatment’ cluster to meet the requirements of the Cancer Mission cluster

Websites, patent fillings, videos etc. (2)

“Diagnosis and treatment” common video and/or a common cluster brochure

"""Diagnosis and treatment"" cluster brochure to meet the requirements of the Cancer Mission cluster."

Project website

A project website will be established to allow dissemination to broader audiences of project objectives and main non-confidential results.

Publikacje

Peer reviewed articles (1)

2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party

Autorzy: Jacqueline Cloos, Peter J. M. Valk, Christian Thiede, Konstanze Döhner, Gail J. Roboz, Brent L. Wood, Roland B. Walter, Sa Wang, Agnieszka Wierzbowska, Andrew H. Wei, David Wu, François Vergez, Adriano Venditti, Bert A. van der Reijden, Arjan A. van de Loosdrecht, Ing Soo Tiong, Felicitas R. Thol, Marion Subklewe, Christophe Roumier, Tom Reuvekamp, Farhad Ravandi, Claude Preudhomme, Adriana Plesa, Jad Othman, Gert J. Ossenkoppele, Yishai Ofran, Aguirre Mimoun, Luca Maurillo, Agata Majchrzak, David de Leeuw, Wolfgang Kern, Dennis Dong Hwan Kim, Maura R. V. Ikoma-Colturato, Lukas H. Haaksma, Monica L. Guzman, Michaela Feuring, Barbara Depreter, Anna Czyz, Veit Bücklein, Constance Baer, Costa Bachas, Sylvie D. Freeman, Francesco Buccisano, Christopher S. Hourigan, Richard Dillon, Michael Heuser
Opublikowane w: Blood, Numer 147, 2026, ISSN 0006-4971
Wydawca: American Society of Hematology
DOI: 10.1182/BLOOD.2025031480